TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04836273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyoPen
Description: multi-dose reusable pen injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HyoPen
Description: multi-dose reusable pen injector

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
Study: NCT05612347

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: One time surveillance colonoscopy
Study: NCT05896059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab，200mg，D1, intravenous，Q3W；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib，12mg，oral administration，QD.
Study: NCT05329623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: All the participants will receive a single oral dose of JDQ443.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: All the participants will receive a single oral dose of JDQ443.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: All the participants will receive a single oral dose of JDQ443.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: All the participants will receive a single oral dose of JDQ443.
Study: NCT06291428

Intervention type: DIAGNOSTIC_TEST
Intervention: Raman spectroscopy
Description: Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect). By analyzing the inelastically scattered light, we can obtain a Raman spectrum formed by the intensity of the scattered light as a function of its vibration frequency, thus obtaining information about the biochemical composition of a biological sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Raman spectroscopy
Description: Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect). By analyzing the inelastically scattered light, we can obtain a Raman spectrum formed by the intensity of the scattered light as a function of its vibration frequency, thus obtaining information about the biochemical composition of a biological sample.
Study: NCT05509296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SINOMED CBC
Description: The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NSE Coronary Dilatation Catheter
Description: The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
Study: NCT06454669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
Study: NCT05856448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT06308692

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ARES PCR
Description: Real time PCR assays will be used for the identification of infecting microorganisms and the drug resistance they carry that allow their identification, such as KPC, VIM, IMP, NDM, Acinetobacter OXA, Oxa48, MCR.~The validation of the method will be carried out in 100 (based on availability in Tropica Biobank) clinical samples: blood n=50 (positive, as for the negatives reference will be made to those already provided in the GENRES study) and rectal swabs ( positive n=40 and negative n=10) provided by the DITM. Sensitivity and specificity will be analyzed. As a reference for positivity and negativity data, reference will be made to routine diagnostic data obtained through standard operating procedures at the DITM laboratories.
Study: NCT05686135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 90Second IBD
Description: Patients will receive 90SecondIBD weekly at no charge via text message or email linked to a website.Each 90SecondIBD letter has an attractive photo, 250 words of targeted information on a specific topic and 3 specific action suggestions on the first page. The second page is a seven-item quiz on attitudes and behavior on the designated topic. The reader gets immediate feedback and advice. The third page is a personal story of someone with IBD about this topic. Finally, there is an evaluation of the specific 90SecondIBD issue and an opportunity to recommend topics.
Study: NCT05946811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10mg
Description: Macitentan 10 mg oral once daily for 3 months. vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Macitentan 10mg
Description: Macitentan 10 mg oral once daily for 3 months. vs placebo
Study: NCT05969015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prochaska and DiClemente transtheorical model
Description: The Prochaska and DiClemente model will be combined to a self-management program in patients with T2DM within 18 months. They will be classified accordingly to their readiness for changing. A care provider will manage the group towards an optimal self-management, aiming to improve their glycemic control and other outcomes of relevance. We will conduct 1 session per week until the end of 12nd intervention month. After, the sections will be conducted each 2 weeks until the end of the trial. Healthcare professional will provide support to the care provider. The recommended processes to progress the patients will be used to trigger them accordingly to their stage, at the discretion of the care provider. We will also consider individualities and non-anticipated problems as a part of the process of behavior changing.
Study: NCT06265350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cadonilimab
Description: Cadonilimab, 375mg，Q3W， IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab, 375mg，Q3W， IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab, 7.5mg/kg，Q3W， IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, 7.5mg/kg，Q3W， IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Patients accepted Cryoablation of pulmanary metastases
Study: NCT05515978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is a medication used to treat type 2 diabetes, gestational diabetes, and prediabetes. In this study, patients on the Metformin arm will be started on 850 mg daily for 2 weeks, then escalated to a final dose of 850 mg twice daily, which is lower than the maximum recommended dose of 2550 mg total daily.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Modification
Description: Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.~Here are some examples of the educational material from the American Diabetes Association website, and topics will be rotated on quarterly basis:~Healthy eating: https://www.diabetes.org/nutrition/healthy-food-choices-made-easy Prediabetes: https://www.diabetes.org/diabetes-risk/prediabetes Fitness: https://www.diabetes.org/fitness/get-and-stay-fit Weight loss: https://www.diabetes.org/fitness/weight-loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.~Here are some examples of the educational material from the American Diabetes Association website, and topics will be rotated on quarterly basis:~Healthy eating: https://www.diabetes.org/nutrition/healthy-food-choices-made-easy Prediabetes: https://www.diabetes.org/diabetes-risk/prediabetes Fitness: https://www.diabetes.org/fitness/get-and-stay-fit Weight loss: https://www.diabetes.org/fitness/weight-loss
Study: NCT05794542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cue X
Description: Cue X is used with augmented (mixed) reality glasses. These glasses are similar to virtual reality glasses except you can see the real world around you with digital images overlain. The Cue X software is used on two existing devices, the Microsoft HoloLens and the Magic Leap.
Study: NCT06359938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial pacing with respiratory sinus arrhythmia (RSA) variability
Description: The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monotonic right atrial overdrive pacing
Description: Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
Study: NCT05074238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc containing suncreen
Description: The study participant will be randomized via a randomization tool within the REDCap database as to which half of the wound (A or B) the patient will be asked to apply zinc containing sunscreen for the duration of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc containing suncreen
Description: The study participant will be randomized via a randomization tool within the REDCap database as to which half of the wound (A or B) the patient will be asked to apply zinc containing sunscreen for the duration of the study.
Study: NCT06496854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Description: 1 mg oral lorazepam, a sedative used to relieve anxiety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: 800 mg ibuprofen, Nonsteroidal anti-inflammatory drug to treat pain
Study: NCT06569771

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional assessments
Description: * Computer Adaptive Test for Fugl-Meyer (CAT-FM)~* Action Research Arm Test (ARAT)~* Measurement of Functional Independence~* Star cancellation test~* Stroke Impact Scale~* ACTIVLIM (assesses the ability to perform activities of daily living requiring the use of the upper limbs)
Study: NCT05510570

Intervention type: GENETIC
Intervention: The research does not require interventions
Description: We use Whole-exome sequence (WES) to analyze if there is any gene mutations for DLD(developmental language disorder) children.
Study: NCT06029413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myo + fascial injection
Description: 10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as well as for fascial layers as described.
Study: NCT03954028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation
Description: Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation
Description: Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.
Study: NCT05289726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional chinese medicine TDX105
Description: Experimental group Traditional chinese medicine TDX105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: he control group received placebo granules mixed with dextrin and food coloring
Study: NCT05586620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-snip punctoplasty
Description: punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-snip punctoplasty and Mitomycin C
Description: punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.~Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis
Study: NCT06483958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: palliative care protocol
Description: 1. Symptom management~2. Respect for patient and family autonomy.~3. Respectful management of clinical information.~4. Provision of holistic care and support.
Study: NCT06029413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional trigger point injection
Description: 10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as described.
Study: NCT06534489

Intervention type: PROCEDURE
Intervention: neoadjuvant immuno-chemotherapy and surgery
Description: After enrolled, patients should receive neo-adjuvant immuno-chemotherapy and a re-evaluation will be performed after treatment to decide surgery strategy.
Study: NCT05170425

Intervention type: DEVICE
Intervention: Prospera
Description: Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of donor derived cell-free DNA (dd-cfDNA) in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

Intervention type: DEVICE
Intervention: Prospera
Description: Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of donor derived cell-free DNA (dd-cfDNA) in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
Study: NCT05480878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500Mg Oral Tablet
Description: All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study: NCT04316104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CuidaTXT
Description: Culturally tailored text messages including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
Study: NCT05175911

Intervention type: OTHER
Intervention: golden hour : an initial standardized stabilization
Description: This is a quality improvement project to evaluate the implementation of Golden hour, a standardized stabilization during the first hour of life in inborn preterm infants younger than 31 weeks of gestational age or weighting less than 1300 g in the NICU of the University of Liege.~There is no comparative arm.
Study: NCT05480878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study: NCT06153524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 12x weekly advice sessions and autonomous physical activity to gradually build up moderate-vigorous exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone time
Description: 12x weekly advice sessions and autonomous use of replacement activities and strategies to gradually reduce daily smartphone use.
Study: NCT05794399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl \>50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range.
Study: NCT06547528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4685
Description: ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed.
Study: NCT06379399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Phase I:~1. 6 patients (male and female) will be enrolled to evaluate safety. Patients will receive Trifluridine/Tipiracil at a dose of 35mg/m2 (maximum single dose of 80 mg). Patients will be followed up for Dose-Limiting Toxicities (DLTs) (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 35mg/m2. If ≥3 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 30mg/m2.~2. Based on the results of the 35mg/m2 dose group, 6 patients (male and female) will be enrolled in the 30mg/m2 dose group to evaluate safety. Patients will be followed up for DLTs (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (1 Cycle, Day 1-Day 28), the study will proceed with a dose of 30mg/m2 in Phase II.~Phase II:~Trifluridine/Tipiracil: po, twice daily from Day 1-5, every two weeks, based on the recommended dose from Phase I;
Study: NCT05855915

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesotaping will be applied with routine physical therapy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sham taping
Description: Sham taping will be applied with routine physical therapy
Study: NCT05885230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pecto intercostal fascial block using bupivacaine 0.25%
Description: patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine infusion
Description: 1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
Study: NCT05642481

Intervention type: DIAGNOSTIC_TEST
Intervention: Therapeutic drug monitoring in plasma of mother and child and in breastmilk
Description: Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
Study: NCT01184287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranpirnase
Description: Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
Study: NCT04881201

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blood sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blood sample